Terns Pharmaceuticals, Inc.
https://www.ternspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Terns Pharmaceuticals, Inc.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Terns Hits In NASH, But Trails Its Rivals
TERN-501 monotherapy looks serviceable in a mid-stage NASH trial, but others are ahead. Perhaps partnership is the way forward.
Genfit/Ipsen’s PBC Data Leave Door Open For CymaBay
Genfit/Ipsen’s elafibranor and CymaBay’s seladelpar are vying to supplant Intercept’s Ocaliva in second-line primary biliary cholangitis, but elafibranor failed to hit a key differentiation endpoint in pruritus.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice